Lilly presents obesity drug trial results at ObesityWeek 2026

Eli Lilly & Co. reported data from obesity drug trials at ObesityWeek 2026. EloraTZP showed 23.3% weight loss at 28 weeks, 60% of patients achieved non-obese BMI at 48 weeks, and 77% reached normal blood glucose levels. Zepbound reduced BMI by 21.4% at 72 weeks in teens. Both drugs improved quality of life. Lilly also claimed retatrutide outperformed Novo Nordisk's Ozempic in weight reduction and blood sugar control.

Eli Lilly will present new data on obesity treatments at ObesityWeek 2026. Phase 2 results show EloraTZP, a combination of eloralintide and tirzepatide, achieved significant weight loss and A1C improvements. Retatrutide reduced sleep apnea severity and knee osteoarthritis pain in Phase 3 trials. Foundayo was reported as easy to use, and eloralintide reduced food cravings and alcohol consumption. Zepbound (tirzepatide) is FDA-approved for obesity and sleep apnea.

Eli Lilly (LLY) will present new data on its obesity treatments at ObesityWeek 2026. Phase 2 results showed EloraTZP, a combination of eloralintide and tirzepatide, achieved significant weight loss and A1C improvements. Retatrutide, an investigational triple agonist, reduced obstructive sleep apnea severity and knee osteoarthritis pain in Phase 3 trials. Foundayo, a GLP-1 pill, was reported as easy to use in a real-world evidence study.

Eli Lilly's oral obesity drug, Orforglipron, received approval in China, competing with Novo Nordisk's Wegovy and other treatments. Lilly's shares rose 1.2% in premarket trading. Novo's shares also increased over 2%. Analysts expect Novo's pill to outperform Lilly's due to superior weight loss results. China's obesity drug market is projected to grow significantly.

Eli Lilly (LLY) began construction on a $3.5 billion plant in Pennsylvania for obesity drugs, including retatrutide, expected to launch by 2031. The company also secured China approval for its weight-loss pill, orforglipron. Lilly's capex rose to $7.84 billion in 2025, but free cash flow reached $8.97 billion in 2023. The company's revenue nearly doubled from 2023 to 2025, with analysts expecting further growth.

China approved Eli Lilly's GLP-1 weight-loss pill, Muyouda, for overweight or obese adults with related conditions. The drug, already approved in the U.S., is the first oral GLP-1 treatment in China, beating competitors like Novo Nordisk. China's weight-loss market is expanding, with 630 million adults projected to be overweight or obese by 2050, according to a 2025 study in The Lancet.